(50), highly expressed DOCK1 led to worse AML prognosis, and higher DOCK1 expression exhibited an obvious relevance to older age, higher platelet and peripheral blast counts, intermediate-risk cytogenetics, FLT3-ITD, MLL-PTD and PTPN11, NPM1, RUNX1, ASXL1 and DNMT3A mutations. This evidence concerns the gene DOCK1 and acute myeloid leukemia.